“Committed to making the difference”
AiCuris is a pharmaceutical company focused on the discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.
Founded in 2006 as a spin-out from Bayer's virology and bacteriology research department, AiCuris is now an established “powerhouse for anti-infectives” and is one of the few biotech companies world-wide to have successfully brought a drug to market, and therefore to patients (Prevymis® 2017/18).
Today AiCuris has an innovative pipeline of anti-infective agents and a team of internationally recognized scientists in Research and Development. By focusing on therapeutic areas with high medical need, the company is positioned for growth and success.
BEAT-COV: Entwicklung COVID-19-Medikamente
|Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente|
AiCuris to Present at J.P. Morgan Conference
|AiCuris to Present at the 39th Annual J.P. Morgan Healthcare Conference|
Dr. Holger Zimmermann, CEO of AiCuris, will present at the 39th Annual J.P. Morgan Healthcare Conference (11-14 Jan., 2021) on:
Thursday, January 14, 2021
at 08:05 am to 08:30 am Eastern Time
(02:05 pm to 02:30 pm Central European Time)
Winners of the AiCubator Resident Status
|AiCuris selects three novel anti-infective treatment approaches as winners of the AiCubator Resident Status, a corporate innovative accelerator initiative|